Drones drop mosquitoes over Maui to save honeycreepers
Conservationists working to save Hawaii's endangered, native birds are now using drones to deliver lab-reared, male mosquitoes over Maui.
The male mosquitoes have a special purpose—to mate with wild females in the forests while carrying a naturally occurring bacteria that results in sterile eggs, thereby breaking the breeding cycle and reducing the population.
Scientists hope this 'incompatible insect technique ' will reduce the overall mosquito population in order to combat avian malaria, the primary cause of decline in Hawaiian honeycreeper species. Over time, they hope these native bird populations will then have a chance to recover.
'Reducing invasive mosquito populations is absolutely critical in preventing the extinction of Hawaii's vulnerable honeycreepers, ' said Chris Farmer, the American Bird Conservancy's Hawaii Director, in a statement. 'We have the technology to break the avian disease cycle in Hawaii, and a fighting chance to restore populations.'
He called the drone deployment a milestone, saying he expects the new technology to expedite the delivery of millions of mosquitoes, with more flexibility.
The first drones were deployed over Maui in April, according to drone pilot Adam Knox, after some engineering to figure out the best way to release them over the remote terrain.
Knox is testing out three different types of drones for the release of the mosquitoes, which are released inside of cone-shaped pods made of biodegradable paper pulp. Each pod contains about 1, 000 mosquitoes.
These pods are placed inside of a special transport box attached to the drone—sort of like a cooler—that keeps the pods at a controlled temperature due to the sensitivities of the male mosquitoes. Several pods are released at a time.
In order to release the pods, Knox, ABC's aerial deployment of mosquitoes project manager, had to work with his team to figure out a release mechanism that would work over mountainous terrain with significant elevation changes, strong winds, frequent rains, and mist.
The drops have to be consistent while flying over thousands of acres despite these challenges.
Knox said the test flights have shown it can be done by drone, which can be more flexible than manual drops via helicopter, without risks to humans on aerial flights.
It is the first known instance of specialized mosquito pods being dropped by drones.
'There is a whole new world out there in terms of utility with this tool, ' Knox said. 'This opens up a lot of possibilities now and into the future.'
Knox expects to continue refining the process, and to test out the drones over Kauai as well, in the near future. Manual drops via contracted helicopters, meanwhile, have been ongoing since November 2023, twice a week, and will continue.
Conservationists are racing to save several Hawaiian birds—specifically native honeycreepers—on the brink of extinction.
Last summer the akikiki on Kauai was declared, meaning only a handful were left in the wild and that the species could not sustain itself in the wild. Some akikiki, however, are being raised in captivity by the San Diego Zoo Wildlife Alliance.
Scientists believe if no action is taken, mosquitoes could cause other Hawaiian bird species to quickly decline and vanish.
Farmer said at least 33 species of honeycreeper are now extinct, and many of the 17 that remain, including the kiwikiu and akohekohe on Maui, and the akekee on Kauai, are highly endangered.
The kiwikiu, or Maui parrotbill, found on the slopes of Haleakala, have a population of less than 150 individuals. The akohekohe, or crested honeycreeper, also found in the high-elevation forests of Haleakala, have a population of fewer than 2, 000.
Due to climate change, mosquitoes have begun to move to higher elevations than in past years, he said, encroaching on the last remaining refuges available to surviving honeycreepers.
The birds are facing numerous obstacles to survival, including habitat loss and degradation due to grazing by hoofed animals, along with invasive predators such as rats that prey on their eggs and chicks.
The No. 1 drivers of the extinction crisis are believed to be mosquito-borne diseases such as avian malaria and avian pox. Scientists say a single bite from an infected mosquito could be fatal to a honeycreeper.
Reducing mosquitoes After years of study and analysis—and a—a multi-agency group made up of ABC, the U.S. Fish and Wildlife Service, Hawaii Department of Land and Natural Resources and others, embarked on the mosquito suppression project.
Collectively, the group calls itself Birds, Not Mosquitoes, and it has stood strongly behind the mission to reduce the invasive southern house mosquito population in high-elevation forests across the state to stem avian malaria.
The male southern house mosquitoes do not bite or transmit diseases, according to experts, but carry a certain strain of Wolbachia bacteria which results in unhatched eggs.
The project was opposed by Hawaii Unites, a nonprofit community group, that in 2023 to stop the multi-agency group from continuing the project.
Hawaii Unites, founded by president Tina Lia, expressed concerns about releasing any 'biopesticide lab-reared Wolbachia-bacteria-infected mosquitoes ' on the fragile ecoystems of Halaekala National Park or Hawaii's other forest reserves.
The group was concerned about unforeseen consequences of releasing the lab-reared mosquitoes.
Both the state Board of Land and Natural Resources and National Park Service had approved a 300-page environment assessment and finding of no significant impact for the project.
Hawaii Unites said a more comprehensive environmental impact statement was needed.
But a state Environmental Court ruled the project could go forward—and following an appeal by Hawaii Unites arguing that the EA did not have enough science and documentation to back its claims of being safe for the environment—an appeals court in April.
Birds, Not Mosquitoes prevailed in obtaining regulatory approvals to move forward on its conservation plan.
Conservation drones It is not the first time drones have been deployed to combat invasive species in Hawaii.
DLNR has shared in recent years that it used drones to drop citric acid over parts of Oahu, including Waimanalo and Kuliouou, in order to help control invasive coqui frog populations.
The deployment of mosquitoes with Wolbachia also has been used in the past in Texas and California, as well as Mexico, Singapore, Thailand and Australia to reduce mosquito-born diseases such as dengue, Zika and Chikungunya.
The use of the incompatible insect technique to help reduce avian malaria in Hawaii, however, is a novel one.
Farmer likes to describe the process as a sort of 'invisible barrier to protect our birds high up in the forests.'
While predator-proof fencing has been erected at refuges and forests to protect birds and ohia trees, this introduction of sterilizing male mosquitoes forms a sort of 'mosquito-proof fence.'
Conservationists believe their mission is time-critical, and that the project must move forward quickly. They are hopeful, but say it will take time to determine how effective this technique is in saving Hawaii's native honeycreepers.
'It takes time to knock them (invasive mosquitoes ) down and to reduce the population, ' Farmer said. 'We're monitoring and analyzing data. As soon as we can tell one way or another, we'll certainly let the public know.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
37 minutes ago
- Bloomberg
Novo Nordisk's CagriSema Shot Tied to Greater Weight Loss at Lower Doses
Novo Nordisk A/S's next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about three-quarters of the patients ever making it to the highest dose. Surprisingly, patients who chose to stick with a lower dose lost more weight on average. The studies allowed patients to stop at lower doses of the drug, an unusual option in a trial. Researchers presenting new data Sunday at the American Diabetes Association meeting in Chicago say the findings offer clues as to how the drug would be used in real life. There's a group of people who respond very well to this medicine, said Timothy Garvey, director of the Diabetes Research Center at the University of Alabama at Birmingham, who helped lead the trials.
Yahoo
an hour ago
- Yahoo
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
By Deena Beasley (Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen. The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine. In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients. In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group. "Everything was in line with what we expected," Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters. The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group. Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. "Those patients on lower doses actually had higher weight loss reduction," she said. "We've not really seen that before because we have not had powerful treatments that have got people close to target." CagriSema is a weekly injection that combines Novo's blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin. The CagriSema Phase 3 trial results "compared very favorably also with what we've seen with tirzepatide, which was previously the best-in-class," Dr. Davies said. Eli Lilly's tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks. Dr. Davies said it makes sense to have more options for patients, including "theoretical benefits" with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body's metabolic adaptation to weight loss, she said. Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026. "We expect to see approval maybe around the beginning of 2027," Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes. Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. "This also allows them to lose their body weight at a pace that isn't too steep. It also mitigates side effects," he said. (Reporting By Deena Beasley, Editing by Franklin Paul) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM
Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions1 When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks1* The REDEFINE clinical program is ongoing to further investigate efficacy and safety of CagriSema, including recently initiated REDEFINE 112 PLAINSBORO, N.J., June 22, 2025 /PRNewswire/ -- Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association's® (ADA) 85th Scientific Sessions and published in NEJM. "In REDEFINE 1, participants saw significant and clinically meaningful weight loss under a protocol that allowed investigators to maintain patients on a submaximal dose if deemed best for the patient. We also witnessed low, single-digit discontinuation rates due to adverse events in both REDEFINE 1 and 2," said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. "These results reinforce our confidence in CagriSema and we continue to study the potential of this combination through the REDEFINE trials." CagriSema is an investigational product that combines the GLP-1 RA, semaglutide, with an amylin analogue, cagrilintide. The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group (estimated difference [95% CI] -20.4 [-21.1 to -19.7]; p<0.001) if all patients adhered to treatment.1* When evaluating the treatment effect regardless of adherence, those treated with CagriSema achieved statistically significant weight loss of 20.4% at 68 weeks versus 3.0% for the placebo group (estimated difference [95% CI] -17.3 [-18.1 to -16.6]; p<0.001).1** In addition, a supportive secondary analysis showed that half (50.7%) of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI <30 kg/m2) at the end of treatment, from a mean BMI of 38 kg/m2 at the start of treatment. In the placebo group, 10.2% reached that threshold at 68 weeks.1 Select confirmatory secondary endpoints showed that if all participants adhered to treatment 40.4% of those receiving CagriSema achieved a body-weight reduction of ≥25% ([95% CI] 39.5 (37.1 to 41.9); p<0.001).* Additionally, 23.1% lost ≥30% of their body weight ([95% CI] 22.7 (20.7 to 24.7); p<0.001).1* When applying the treatment policy estimand, 34.7% of participants treated with CagriSema achieved ≥25% body-weight reduction ([95% CI] 33.7 (31.5 to 35.9); p<0.001) and 19.3% achieved ≥30% body-weight reduction ([95% CI] 18.9 (17.1 to 20.7); p<0.001).1** In a prespecified analysis of 252 participants, the relative reduction in fat and lean soft-tissue mass from baseline to week 68 was -35.7% (fat mass) and -14.4% (lean soft-tissue mass) for those treated with CagriSema versus -5.7% and -4.3% for the placebo group, respectively. "In REDEFINE 1, CagriSema provided weight loss in the highest range of efficacy observed with existing weight loss interventions," said lead investigator Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham. "Investigators were allowed some flexibility in dose adjustments to balance efficacy and safety, but regardless of dose adjustments participants lost significant weight. These findings are relatable to clinical practice, where dosing is often adjusted based on individual needs and clinical judgement." Safety data generated in the REDEFINE 1 and 2 trials was comparable with the GLP-1 RA class. Overall, discontinuation rates due to adverse events were low, with 6% for CagriSema versus 3.7% for placebo in REDEFINE 1 and 8.4% with CagriSema versus 3% with placebo in REDEFINE 2.1,3 In REDEFINE 1, adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs 39.9% with placebo) including nausea (55% vs 12.6%), constipation (30.7% vs 11.6%), vomiting (26.1% vs 4.1%) and were mostly transient and mild-to-moderate in severity.1 Results from REDEFINE 2, a phase 3 study that evaluated the efficacy and safety of CagriSema plus lifestyle interventions in adults with obesity and type 2 diabetes (T2D), were also simultaneously presented during a scientific symposium at the ADA's Scientific Sessions and published in NEJM.3 In REDEFINE 2, if all participants adhered to treatment, the estimated mean change in body weight from baseline to week 68 was -15.7% with CagriSema versus -3.1% with placebo (estimated difference [95% CI] -12.6% [-13.4 to -11.7]; p<0.001).3* When applying the treatment policy estimand, the estimated mean change in body weight from baseline to week 68 was -13.7% with CagriSema versus -3.4% with placebo (estimated difference [95% CI] -10.4% [-11.2 to -9.5]; p<0.001).3** A greater proportion of participants receiving CagriSema, compared with placebo, reduced their body weight by >5% (83.6% vs 30.8% of participants; p<0.001), ≥10% (65.6% vs 10.3%), ≥15% (43.9% vs 2.4%), and ≥20% (22.9% vs 0.5%; p<0.001).3 The safety results from CagriSema in REDEFINE 2 were similar to those reported in REDEFINE 1.3 The REDEFINE clinical program will continue to assess the efficacy and safety of CagriSema. Most recently, Novo Nordisk initiated the REDEFINE 11 trial with the first patient visit occurring in early June 2025. REDEFINE 11 will explore further weight loss potential and safety of CagriSema 2.4 mg / 2.4 mg through a longer trial duration and other protocol changes compared to REDEFINE 1 and 2. * Based on the trial product estimand: this estimand estimates what the effect would be if all participants adhered to treatment** Based on the treatment policy estimand: treatment effect regardless of treatment adherence About CagriSemaCagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program). CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. CagriSema is not approved in the US for weight loss. About the REDEFINE clinical trial programREDEFINE is a phase 3 clinical development program with once-weekly subcutaneous CagriSema in obesity. REDEFINE 1 and REDEFINE 2 have enrolled approximately 4,600 adults with overweight or obesity. REDEFINE 1 was a 68-week, double-blind, placebo- and active-controlled efficacy and safety phase 3 trial of once-weekly CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg versus placebo in 3,417 adults with obesity or overweight with one or more comorbidities and without type 2 diabetes. REDEFINE 2 was a double-blind, randomized, placebo-controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema versus placebo in 1,206 adults with type 2 diabetes and either obesity or overweight. Multiple REDEFINE clinical trials are currently underway including: REDEFINE 3, an event-driven cardiovascular outcomes phase 3 trial; REDEFINE 4 an 84-week head-to-head efficacy and safety phase 3 trial of once-weekly CagriSema versus once-weekly tirzepatide; and REDEFINE 11, a phase 3 trial with longer duration and other protocol changes compared to REDEFINE 1 and 2. About obesityObesity is a serious chronic, progressive, and complex disease that requires long-term management.4-6 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.4,6 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.7,8 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.9,10 In the US, about 40% of adults live with obesity.11 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information Media:Liz Skrbkova (US)+1 609 917 0632USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Investors:Frederik Taylor Pitter (US)+1 609 613 0568fptr@ Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@ Sina Meyer (Global)+45 3079 6656 azey@ Ida Schaap Melvold (Global)+45 3077 5649 idmg@ Max Ung (Global)+45 3077 6414mxun@ References: Garvey T, Blüher M, Contreras C, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;10.1056/NEJMoa2502081. A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term. Last Accessed: June 2025. Available at: Davies M, Bajaj H, Broholm C, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;10.1056/NEJMoa2502082. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61-69. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Rev. 2017;18(7):715-723. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1-203. Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: June 2025. Available at: World Obesity Federation. World Obesity Atlas 2023. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Why it matters. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023. Last accessed June 2025. Available at: View original content to download multimedia: SOURCE NOVO NORDISK INC. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
